what the cause of this observation may be. Nonetheless, Brimonidine tartrate is more soluble in solution with a 1.5% CMC than with no CMC.

CMC is also effective to solubilize Brimonidine tartrate in a biological environment, for example the biological environment of the cornea.

EXAMPLE 3

Brimonidine tartrate dimers.

Brimonidine tartrate is added to a test tube containing a composition including chlorite. The test tube was allowed to equilibrate for ten days. Samples obtained from the test tube is analyzed. It is observed that a portion of the Brimonidine tartrate monomer units conjugated to form dimers.

While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced with the scope of the following claims.

WHAT IS CLAIMED IS:

1. A composition comprising:

an alpha-2-adrenergic agonist component in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;

a solubility enhancing component in an amount effective to increase the solubility of the alpha-2-adrenergic agonist component in the composition relative to the solubility of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component; and

a liquid carrier component.

2. The composition of claim 1 wherein the alpha-2-adrenergic agonist component is selected from the group consisting of imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, derivatives thereof and mixtures thereof.

3. The composition of claim 1 wherein the therapeutically active component includes a quinoxaline component.

4. The composition of claim 3 wherein the quinoxaline component is selected from the group consisting of quinoxaline, derivatives thereof, and mixtures thereof.

5. The composition of claim 3 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, and tartrate of 5-bromo-6-(2-imidozolin-2-

ylamino) quinoxaline, derivatives thereof and mixtures thereof.

6. The composition of claim 1 wherein the therapeutically active component comprises a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline.

7. The composition of claim 1 wherein the alpha-2-adrenergic agonist component is substantially unionized.

8. The composition of claim 1 wherein the alpha-2-adrenergic agonist component is substantially unionized in a biological environment to which the composition is administered.

9. The composition of claim 1 wherein the alpha-2-adrenergic agonist component has increased diffusion through a lipid membrane relative to an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component.

10. The composition of claim 1 wherein the alpha-2-adrenergic agonist component is selected from the group consisting of agonists of alpha-2A-adrenergic receptors, agonists of alpha-2B-adrenergic receptors, agonists of alpha-2D-adrenergic receptors and mixtures thereof.

11. The composition of claim 1 wherein the solubility enhancing component is effective to increase the solubility in a biological environment of the alpha-2-adrenergic agonist component relative to the solubility in a biological environment of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component.

12. The composition of claim 1 wherein the solubility enhancing component comprises a polyanionic component.

13. The composition of claim 12 wherein said polyanionic component is selected from the group consisting of anionic cellulose derivatives, anionic polymers derived from acrylic acid, anionic polymers derived from methacrylic acid, anionic polymers derived from alginic acid, anionic polymers derived from amino acids and mixtures thereof.

14. The composition of claim 1 wherein the solubility enhancing component is selected from the group consisting of anionic cellulose derivatives and mixtures thereof.

15. The composition of claim 1 wherein the solubility enhancing component is selected from the group consisting of carboxymethylcelluloses and derivatives thereof.

16. The composition of claim 1 wherein the solubility enhancing component is present in an amount in a range of about 0.1% (w/v) to about 30% (w/v).

17. The composition of claim 1 wherein the solubility enhancing component is present in an amount in a range of about 0.2% (w/v) to about 10% (w/v).

18. The composition of claim 1 wherein the solubility enhancing component is present in an amount in a range of about 0.2% (w/v) to about 0.6% (w/v).

19. The composition of claim 1 wherein the liquid carrier component is an aqueous liquid carrier component.

20. The composition of claim 1 which is a solution.

21. The composition of claim 1 which has a pH of about 7 or greater.

22. The composition of claim 1 which has a pH in a range of about 7 to about 9.

23. The composition of claim 1 which is ophthalmically acceptable.

24. A composition comprising:

an alpha-2-adrenergic agonist component in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;

an anionic cellulose derivative in an amount effective to increase the solubility of the alpha-2-adrenergic agonist component; and

an aqueous liquid carrier component.

25. The composition of claim 24 wherein the alpha-2-adrenergic agonist component comprises a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline.

26. The composition of claim 24 wherein the anionic cellulose derivative comprises carboxymethylcellulose.

27. The composition of claim 24 wherein the anionic cellulose derivative is present in an amount in a range of about 0.2% (w/v) to about 0.6% (w/v).

28. A composition comprising:

a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;

a solubility enhancing component in an amount effective to increase the solubility of the tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline; and

an aqueous liquid carrier component.

29. The composition of claim 28 wherein the solubility enhancing component comprises a carboxymethylcellulose.

30. The composition of claim 28 which is ophthalmically acceptable.

31. A complex comprising monomer units derived from one or more quinoxaline components.

32. The complex of claim 31 wherein the quinoxaline component is selected from the group consisting of a quinoxaline, a (2-imidozolin-2-ylamino) quinoxaline, a 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, derivatives thereof and mixtures thereof.

33. The complex of claim 31 wherein the quinoxaline component is a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline.

34. An oligomer comprising monomer units derived from a quinoxaline component.

35. The oligomer of claim 34 wherein the quinoxaline component is selected from the group consisting of a quinoxaline, a (2-imidozolin-2-ylamino) quinoxaline, a 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, derivatives thereof and mixtures thereof.

36. The oligomer of claim 34 wherein the quinoxaline component is a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline.

37. The oligomer of claim 34 which is a dimer.

38. The oligomer of claim 35 which is a dimer.

39. The oligomer of claim 36 which is a dimer.

40. A composition comprising:

an alpha-2-adrenergic agonist component in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;

an oxy-chloro component in an effective amount to at least aid in preserving the composition; and

a liquid carrier component,

wherein the composition is substantially free of cyclodextrins.

41. The composition of claim 40 wherein the alpha-2-adrenergic agonist component is selected from the group consisting of imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, derivatives thereof and mixtures thereof.

42. The composition of claim 40 wherein the

therapeutically active component includes a quinoxaline component.

43. The composition of claim 42 wherein the quinoxaline component is selected from the group consisting of quinoxaline, derivatives thereof, and mixtures thereof.

44. The composition of claim 40 which further includes a solubility enhancing component in an amount effective to increase the solubility of the alpha-2-adrenergic agonist component in the composition relative to the solubility of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component.

45. The composition of claim 44 wherein the solubility enhancing component is effective to increase the solubility in a biological environment of the alpha-2-adrenergic agonist component relative to the solubility in a biological environment of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component.

46. The composition of claim 44 wherein the solubility enhancing component comprises a polyanionic component.

Add A^2.

add R^4

DECLARATION FOR PATENT APPLICATION

D-2892

As a below named inventor, I hereby declare that:

My residence post office address and citizenship are as stated below next to my name.
I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS** the specification of which

(check one) [X] is attached hereto
[ ] was filed on
as US Application Serial Number or PCT International Application Number
and was amended on ___ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose information which is material to the patentability as defined in 37 CFR § 1.56.
I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. NONE

Prior Foreign Application(s) Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	[ ]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

60/218,200	July 14, 2000
(Application Number)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT International application designation the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application. NONE

(Application Number)	(Filing Date)	(Status -patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Martin A. Voet, Reg. No. 25,208, Robert Baran, Reg. No. 25,806, Carlos A. Fisher, Reg. No. 36,510, Stephen Donovan, Reg. No. 33,433 and Frank J. Uxa, Reg. No. 25,612

Address all telephone calls to Frank J. Uxa - Telephone: 949-450-1750
Address all correspondence to Frank J. Uxa
4 Venture, Suite 300
Irvine, CA 92618

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, ~~family~~ family name) OREST OLEJNIK

Inventor's signature _____ Date 7/9/01
Residence Coto de Coza, CA Citizenship U.S.A.
Post Office Address 5 Addington Place
Coto de Coza, CA 92679

Full name of second inventor (given name, family name) EDWARD D.S. KERSLAKE

Inventor's signature _____ Date 7/3/2001
Residence Charleston, MA Citizenship ~~U.S.A.~~ U.K
Post Office Address ~~30 Elm Street, #1~~
~~Charleston, MA 02129~~
26 MOUNT VERNON
CHARLESTOWN
MA, ~~30~~ 02129

FORM PTO-1595
(Rev. 6-93)
OMB No. 0651-0011 (exp. 4/94)

CORDATION FORM COVER SHE
PATENTS ONLY

U.S. DEPARTMENT OF COMMEF
Patent and Trademark Of

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
OREST OLEJNIK
EDWARD D.S. KERSLAKE

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)
Name: ALLERGAN SALES, INC.
Internal Address: PO BOX 19534

Street Address: 2525 DUPONT DRIVE
IRVINE, CA 92612

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:
☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other: _____
Execution Date: JULY 3RD AND 9TH, 2001

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: JULY 3 & 9, 2001
A. Patent Application No.(s)
B. Patent No. (s)
Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: ALLERGAN, INC.
Internal Address: PO BOX 19534
Street Address: 2525 DUPONT DRIVE
IRVINE, CA 92612

6. Total number of applications and patents involved: [ ]

7. Total fee (37 CFR 3.41).....$ 40
☐ Enclosed
x Authorized to be charged to deposit account

8. Deposit account number: 01-0885
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

FRANK J. UXA
Name of Person Signing

Signature

July 10, 2001
Date

Total number of pages including cover sheet, attachments and document: 3

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box assignments
Washington, D.C. 20231

ASSIGNMENT

WHEREAS we, Orest Olejnik of ORANGE COUNTY, CALIFORNIA and Edward D.S. Kerslake of SUFFOLK COUNTY, MASSACHUSETTS (hereinafter referred to as ASSIGNOR), have invented and own a certain invention entitled: COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS for which I have executed a provisional application, and non-provisional application claiming priority thereto, for Letters Patent of the United States, said provisional patent application having been filed July 14, 2000 and bearing Serial No. 60/218,200 and said non-provisional application for which application for Letters Patent of the United States has been executed on even date herewith.

WHEREAS: Allergan Sales, Inc., having its principal place of business at 2525 Dupont Drive, Irvine, CA 92612 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire interest in, to and under said invention and in, to and under Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar ($1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the full and exclusive right, title and interest to said invention in the United States and its territorial possessions and in all foreign countries to all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application or any continuation, divisional, renewal, substitute or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent and legal equivalents in foreign countries as may be known and accessible to ASSIGNOR and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalent thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

7/9, 2001.

OREST OLEJNIK

State of CALIFORNIA)
) ss:
County of ORANGE)

On JULY 9, 2001 before me, MARY LOU McNOWN personally appeared OREST OLEJNIK personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person, or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

MARY LOU MCNOWN
Commission # 1229524
Notary Public - California
Orange County
My Comm. Expires Aug 16, 2003

Mary Lou McNown
Notary Public

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

7/3, 2001.

EDWARD D.S. KERSLAKE

State of MASSACHUSETTS)
) ss:
County of Suffolk)

On July 3, 2001 before me, Maureen Vibert, Notary Public personally appeared Edward D.S. Kerslake personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person, or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Maureen R Vibert
Notary Public
My Commission expires: 11/6/2006

PRINT OF DRAWINGS
AS ORIGINALLY FILED

10236566 .090602



10236566.090502

APPLICATION DATA SHEET

Inventor Information

Inventor One Given Name::	Orest
Family Name::	Olejnik
Postal Address Line One::	5 Addington Place
Postal Address Line Two::	
City::	Coto de Coza
State or Province::	CA
Postal or Zip Code::	92679
Citizenship Country::	USA

Inventor Two Given Name::	Edward D.S.
Family Name::	Kerslake
Postal Address Line One::	26 Mount Vernon
Postal Address Line Two::	
City::	Charlestown
State or Province::	MA
Postal or Zip Code::	02129
Citizenship Country::	UK

Correspondence Information

USPTO Customer Number::	33,197
Name Line One::	Frank J. Uxa
Name Line Two::	Stout, Uxa, Buyan & Mullins, LLP
Address Line One::	Suite 300
Address Line Two::	4 Venture
City::	Irvine
State or Province::	CA
Postal or Zip Code::	92618
Telephone::	949-450-1750
Fax::	949-450-1764
Electronic Mail::	fjuxa@patlawyers.com

10236566 .090602

Application Information

Title Line One::	Compositions Containing Alpha-2-Adrenergic
Title Line Two::	Agonist Components
Total Drawing Sheets::	1
Formal Drawings?::	Yes
Application Type::	Utility

Representative Information

Registration Number One::	Frank J. Uxa, Jr.	25,612
Registration Number Two::	Donald E. Stout	34,493
Registration Number Three::	Robert D. Buyan	32,460
Registration Number Four::	Kenton R. Mullins	36,331
Registration Number Five::	Jo Anne M. Ybaben	42,243
Registration Number Six::	Linda Allyson Fox	38,883
Registration Number Seven::	Kyle D. Yesland	45,520
Registration Number Eight::	Ketan Vakil	43,215
Registration Number Nine::	Greg S. Hollrigel, Ph. D.	45,374
Registration Number Ten::	Martin A. Voet	25,208
Registration Number Eleven::	Robert J. Baran	25,806
Registration Number Twelve::	Carlos A. Fisher	36,510
Registration Number Thirteen::	Stephen Donovan	33,433

Continuity Information

This application is a::	Regular
>Application One::	60/218,200
Filing Date::	July 14, 2000

This application is a::	Continuation
>Application One::	09/904,018
Filing Date::	July 10, 2001

Assignment Information

102365 090602

Assignee Name::	Allergan Sales, Inc.
Postal Address Line One::	2525 Dupont Drive
Postal Address Line Two::	
City::	Irvine
State or Province::	CA
Postal or Zip Code::	92612

9-9-02 10236566 .090602

S(S 10/97)

J1025 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No
D-2892CON

Total Pages in this Submission

JC979 U.S. PTO 10/236566

TO THE COMMISSIONER FOR PATENTS
Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 CFR 1.53(b) is a new utility patent application for an invention entitled:

COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS

and invented by:

OLEJNIK ET AL

If a CONTINUATION APPLICATION, *check appropriate box an supply the requisite information:*
[x**Continuation** [ ]**Divisional** [ ]**Continuation-in-part (CIP)** of prior application No.: **09/904,018 filed July 10, 2001, which, in turn , claims the benefit of U.S. Provisional Application Serial No. 60/218,200, filed July 14, 2000.**

Enclosed are **Application Elements:**

[x] Filing Fee
[x] Specification having 40 page(s) and including the following:
- [x] Title of the Invention
- [X] Cross References to Related Applications *(if applicable)*
- [x] Background of the Invention
- [x] Brief Summary of the Invention
- [x] Description of the Drawings
- [x] Detailed Description
- [x] Claim(s) as Classified Below
- [x] Abstract of the Disclosure

[x] 1 Sheets of Drawings(s) (37 CFR 113) [X] Formal [ ] Informal
[x] Oath or Declaration [x] Executed [ ] Unexecuted
[x] Copy from prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
[x] Power of Attorney [x] Executed [ ] Unexecuted
[x] Copy from prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
[ ] Incorporation By Reference -- The entire disclosure of the prior application from which a copy of the oath or declaration is supplied under the above entry, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
[ ] Computer Program in Microfiche *(Appendix)*

Accompanying Application Parts

[x] Assignment Papers (cover sheets & documents(s))
[x] The prior application is assigned of record to **Allergan Sales, Inc.**
[x] Copy from prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
[ ] 37 CFR 3.73(B) Statement *(when there is an assignee)*

[illegible]

[ ] English Translation Docume *(applicable)*
[x] Information Disclosure Statement/PTO-1449 [ ] Copies of _ IDS Cited Reference(s)
[x] Preliminary Amendment
[x] Acknowledgment postcard
[ ] Copy from prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
[x] Certificate of Mailing by Express Mail
[ ] Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

Fee Calculation and Transmittal

** The filing fee is calculated on the basis of the claims existing in the prior application as amended by the accompanying preliminary amendment noted above.*

CLAIMS AS FILED					
For	**#Filed**	**#Allowed**	**#Extra**	**Rate**	**Fee**
Total Claims	20	- 20 =	0	X $18.00	$0.00
Independent Claims	2	- 3 =	0	X $80.00	$ 0.00
Multiple Dependent Claims *(check if applicable)* [ ]					$ 0.00
				BASIC FEE	$740.00
OTHER FEE *(specify purpose) ASSIGNMENT RECORDATION FEE*					
(Applicant has small entity status under 37 CFR 1.9 and 1.27)				**SMALL ENTITY STATUS**	--
				TOTAL FILING FEE	$740.00

[ ] A check in the amount of $ ___ to cover the filing fee and the assignment fee is enclosed.
[x] The Commissioner is hereby authorized to charge and/or credit Deposit Account Number **01-0885** as described below.
  [x] Charge the amount of **$740.00** as filing fee and assignment fee.
  [x] Credit any overpayment.
  [x] Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

Respectfully Submitted,

Frank J. Uxa
Attorney for Applicants
Registration Number: 25,612

Stout, Uxa, Buyan & Mullins, LLP
4 VENTURE, SUITE 300, IRVINE, CA 92618
phone (949) 450-1750; *fax* (949) 450-1764

EXHIBIT F , TAB 2

10235656.030602

#21A
11/1/02

D-2892CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In the application of:
Olejnik et al

Serial No. N/A

Filing Date: HEREWITH

For: COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS

Group Art Unit: N/A

Examiner: N/A

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Please amend the subject application as follows:

IN THE SPECIFICATION

Page 1, delete the first paragraph and insert in place thereof:

A1 --This application is a continuation of application Serial No. 09/904,018, filed July 10, 2001 which, in turn, claims the benefit of U.S. Provisional Application Serial No. 60/218,200, filed July 14, 2002. The disclosure of each of the above-noted applications is incorporated in its entirety herein by reference.--

IN THE CLAIMS

Cancel Claims 1 to 46, without prejudice.

Add new claims 47 to 66 as follows:

A2 Sub B' 47. (New Claim) A composition comprising;

A

10236566.090502

water; and

up to about 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate, the composition having a pH of about 7.0 or greater, and the 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate being soluble in the composition at 21°C.

48. (New Claim) The composition of claim 47 which includes up to 0.15%(w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate.

49. (New Claim) The composition of claim 47 which includes about 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate.

50. (New Claim) The composition of claim 47 which includes 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate.

51. (New Claim) The composition of claim 47 having a pH of 7.0 or greater.

52. (New Claim) The composition of claim 47 which is ophthalmically acceptable.

53. (New Claim) The composition of claim 47 which further comprises an oxy-chloro component in an amount effective to at least assist in preserving the composition.

54. (New Claim) The composition of claim 53 wherein the oxy-chloro component comprises a chlorite component.

55. (New Claim) The composition of claim 47 which is

10236566.090602

substantially free of anionic cellulosic derivatives.

9 ~~56~~. (New Claim) The composition of claim ~~47~~ 1 which is substantially free of carboxymethyl cellulose.

AP cont'd

Sub B3

57. (New Claim) A composition comprising:
water; and
up to about 0.15% (w/v) of a component selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline, salts of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline, esters of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline and mixtures thereof, the composition having a pH of about 7.0 or greater, and the component being soluble in the composition at 21°C.

11 ~~58~~. (New Claim) The composition of claim ~~57~~ 10 which includes up to 0.15% (w/v) of the component.

12 ~~59~~. (New Claim) The composition of claim ~~57~~ 10 which includes about 0.15% (w/v) of the component.

13 ~~60~~. (New Claim) The composition of claim ~~57~~ 10 which includes 0.15% (w/v) of the component.

14 ~~61~~. (New Claim) The composition of claim ~~57~~ 10 having a pH of 7.0 or greater.

7 C

62. (New Claim) The composition of claim 57 which is ophthalmically acceptable.

15 ~~63~~. (New Claim) The composition of claim ~~57~~ 10 which further comprises an oxy-chloro component in an amount effective to at least assist in preserving the composition.

14 ~~64.~~ (New Claim) The composition of claim ~~63~~ 15 wherein the oxy-chloro component comprises a chlorite component.

AP cont'd

15 ~~65.~~ (New Claim) The composition of claim ~~57~~ 10 which is substantially free of anionic cellulosic derivatives.

16 ~~66.~~ (New Claim) The composition of claim ~~57~~ 10 which is substantially free of carboxymethyl cellulose.

REMARKS

The specification has been amended to make reference to prior, related applications.

Claims 1 to 46 have been canceled, without prejudice.

New claims 47 to 66 have been added and are directed to embodiments for which patent protection is sought. Each of these new claims is fully supported by the present specification.

Applicant respectfully requests early and favorable action in the above-identified application.

Respectfully submitted,

Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

FJUxa/jm

EXHIBIT F , TAB 3

#3

D D-2892CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

JC979 U.S. PTO
10/236566
09/06/02

In the application of:
Olejnik et al

Group Art Unit: N/A

Serial No. N/A

Examiner: N/A

Filing Date: HEREWITH

For: COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

Some of these documents were cited in related application Application Serial No. 09/904,018, filed July 10, 2001 and Application Serial No. 09/903,962, filed July 10, 2001.

Therefore, no copies of these documents are submitted herewith.

Respectfully submitted,

Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

FJUxa/au



DOCKET NO.: D-2892CON

THE ENCLOSED PATENT APPLICATION OF OLEJNIK ET AL IS BEING FILED IN ACCORDANCE WITH SECTION 37 CFR 1.10 BY EXPRESS MAIL AND SHOULD BE ACCORDED A FILING DATE OF:

September 6, 2002

SEE THE EXPRESS MAIL CERTIFICATE ATTACHED TO THE APPLICATION.

Sheet 1 of 1

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

DOCKET NO: D-2892CON | APPLN. NO.: N/A

APPLICANT: Olejnik et al

FILING DATE: Herewith | GROUP ART: N/A

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RB	3 2 7 8 4 4 7	10/11/66	McNicholas			
	3 8 9 0 3 1 9	06/17/75	Danielwicz et al.			
	4 5 3 0 9 2 0	07/23/85	Nestor et al.			
	4 8 0 6 5 5 6	02/21/89	Portoghese			
	5 0 2 1 4 1 6	06/04/91	Gluchowski			
	5 2 0 2 1 2 8	04/13/93	Morella et al.			
	5 3 5 2 7 9 6	10/04/94	Hoeger et al.			
	5 4 5 9 1 3 3	10/17/95	Neufeld			
	5 7 0 3 0 7 7	12/30/97	Burke et al.			
	5 7 1 9 1 9 7	02/17/98	Kanios et al.			
	5 7 2 5 8 8 7	03/10/98	Martin et al.			
	5 8 1 4 6 3 8	09/29/98	Lee et al.			
	5 8 3 4 5 0 2	11/10/98	Cheng et al.			
RB	5 9 9 4 1 1 0	11/30/99	Mosbach et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
RB	2 0 4 8 3 1 5	02/09/92	Canada				
	0 6 0 9 9 6 1	08/10/94	European				
	94 / 1 6 6 8 5	08/04/94	~~International~~ WIPO				
	98 / 4 7 8 7 8	10/29/98	~~International~~ WIPO				
	99 / 4 3 2 9 9	09/02/99	~~International~~ WIPO				
	99 / 5 1 2 7 3	10/14/99	~~International~~ WIPO				
	00 / 1 2 1 3 7	03/09/00	~~International~~ WIPO				
RM	00 / 1 9 9 8 1	04/13/00	~~International~~ WIPO				

OTHER DOCUMENTS

RB		U.S. Patent Application Serial No. 09/903,962, filed July 10, 2001

EXAMINER: Rachel M. Bennett

DATE CONSIDERED: 12/10/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.